Kraig Biocraft Laboratories Inc. is a biotech company working to develop and commercialize high performance polymers. The company intends to break into the $92 billion market for high performance fibers by using spider silk genes.

The company intends to insert these genes into silkworms to make them produce fibers with the characteristics of spider silk, which is one of the strongest natural fibers known. In an effort to reach these goals, Kraig Biocraft has licensed the spider gene sequences patented by the University of Wyoming and the genetic developed technology by the University of Notre Dame.

Several weeks ago, Kraig Biocraft announced that during the months of May, June and July the scientific team succeeded in its previously announced attempt to ramp up the number of genetic insertions performed. The team’s initial goal was to double the number of DNA construct insertions performed in

Kraig Biocraft Laboratories Inc. is a biotech company working to develop and commercialize high performance polymers. The company intends to break into the $92 billion market for high performance fibers by using spider silk genes.

The company intends to insert these genes into silkworms to make them produce fibers with the characteristics of spider silk, which is one of the strongest natural fibers known. In an effort to reach these goals, Kraig Biocraft has licensed the spider gene sequences patented by the University of Wyoming and the genetic developed technology by the University of Notre Dame.

Several weeks ago, Kraig Biocraft announced that during the months of May, June and July the scientific team succeeded in its previously announced attempt to ramp up the number of genetic insertions performed. The team’s initial goal was to double the number of DNA construct insertions performed in

Kraig Biocraft Laboratories, Inc. was pleased to announce this morning that during the months of May, June and July the scientific team achieved its previously announced goal to significantly ramp up the number of genetic insertions performed. The team’s initial goal was to double the number of DNA construct insertions performed in May. However, the actual number of insertions performed greatly exceeded that goal and the increase was sustained in June and July as well.

“Over the last ninety days, Dr. Fraser’s team has performed tens of thousands of DNA construct insertions. This increase in laboratory productivity greatly exceeded management’s expectations for the period,” stated CEO Kim K. Thompson. “This dramatic increase in productivity is an indication of the dedication and enthusiasm of the scientists. We know that each insertion has the potential to create a new recombinant fiber with commercial applications.”

Let us

Kraig Biocraft Laboratories Inc. develops protein-based fiber using recombinant DNA technology. The company focuses on spider silk because of its exceptional strength and durability. Some spiders produce up to seven different types of silk, depending on its use, for catching prey, spinning a web, or traveling.

Since spiders are cannibals and hard to keep in colonies, the company maintains its focus on reproducing the fibers using transgenic silkworms. The idea is to create a transgenic variety of silkworms capable of spinning a new “super fiber” that is similar or an exact copy of natural spider silk, which is can be used in military and police departments, industrial and consumer applications, as well as for the aero-space industry.

In May of this year, Kraig Biocraft announced that it has successfully created eight DNA constructs, with the help of a team of scientists. Having teamed up

Kraig Biocraft Laboratories, Inc. was pleased to announce this morning that it has successfully issued its stock dividend.

CEO Kim K. Thompson stated, “The issuance of the dividend has been in the planning for some time and has been an important part of the Company’s plan for returning value to our shareholders. Just as important, we believe that the issuance has laid the groundwork for the Company’s long term future.”

He continued, “The input we have received from our shareholders throughout this process has been and continues to be overwhelmingly positive. We are also very excited about the progress in the laboratory and are very hopeful that the scientific team can maintain their tremendous forward momentum through the summer and fall and into 2010.”

Let us hear your thoughts: Kraig Biocraft Laboratories, Inc. Message Board

Kraig Biocraft Laboratories Inc. develops protein-based fiber using recombinant DNA technology. The company uses spider silk because of its exceptional strength and durability. Some spiders produce up to seven different types of silk, depending on its use, for catching prey, spinning a web, or traveling.

Since spiders are cannibals and hard to keep in colonies, the company maintains its focus on reproducing the fibers, mimicking nature as much as it can. The fibers can be used in military and police departments, industrial and consumer applications, as well as for the aero-space industry.

Earlier this month, Kraig Biocraft announced that it, along with a team of scientists, successfully created eight DNA constructs, which they plan on using for genetic insertion in the upcoming weeks. Having teamed up with the University of Notre Dame to move into the $92 billion market for technical fibers, the news is a

Kraig Biocraft Laboratories, Inc. announced that Dr. Malcolm Fraser, Dr. Wang, Dr. Sohn and other members of the scientific team are preparing for the genetic insertion of recently created DNA constructs. The genetic constructs are customized packets of DNA that provide genetic instructions for the creation of new polymers and spider silk-based proteins. These unique genetic insertion packets include several that are specifically designed for the production of new fusion silk proteins.

CEO Kim K. Thompson stated, “These constructs include a number of new DNA combinations that are truly exciting. The increases in laboratory productivity over the last eight months are now enabling us to do more and to do it faster. This number of unique genetic constructs is a new breakthrough for the Company. Each of these constructs has the potential to result in the development of a new polymer or high performance fiber.”

After the closing bell today, Kraig Biocraft Laboratories, Inc. announced that the record date for the recently declared stock dividend will be April 27, 2009. Shareholders of record as of the close of business on this date will be issued nine additional shares for each share of Common Stock held.

CEO Kim K. Thompson recently commented, “This stock dividend is intended to lay the groundwork for the growth of the Company. It is part of our ongoing efforts to improve trading liquidity, broaden ownership, promote capital investment and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to create a wider distribution of the Company’s stock.”

Let us hear your thoughts: Kraig Biocraft Laboratories, Inc. Message Board

Kraig Biocraft Laboratories, Inc. was very pleased to announce this morning that scientists working in the company’s sponsored research program at the University of Notre Dame have significantly increased the number and proportion of DNA insertions that yield transient expression of the company’s targeted marker protein.

“These results, which are occurring in the latest generation of genetic insertions performed in the laboratory, are very exciting, and we believe that it is further evidence that the research team is on the right track,” commented CEO Kim K. Thompson.

This increase is in both absolute numbers and in the percentage of insertions, which ultimately result in the expression. This morning’s news follows closely on the heels of other progress reports, announcing to investors the significant achievements made over the last six months.

“This is the first time we have seen the number of DNA insertions yielding transient

Today, Kraig Biocraft Laboratories, Inc. announced that its Board of Directors has approved a stock dividend. According to the press release, shareholders of record as of the close of business on the record date will be issued nine additional shares for each share of Common Stock held.

CEO Kim K. Thompson commented, “This stock dividend is intended to lay the groundwork for the growth of the Company. It is part of our ongoing efforts to improve trading liquidity, broaden ownership, promote capital investment and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to create a wider distribution of the Company’s stock.”

The Board of Directors has directed the company’s management to speak with market oversight authorities and its transfer agents as soon as is practical to designate a record